Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Repligen Corporation Common Stock — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.76 (market cap $7.96B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Repligen Corporation Common Stock for 0 Days on average.
| PDBC | RGEN | |
|---|---|---|
Market Cap | $7.96B | $11.14B |
Volume | 2,738,146 | 1,259,263 |
52-Week High | $20.10 | $194.57 |
52-Week Low | $13.19 | $102.87 |
Typical Hold Time | 56 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC, an ETF tracking diversified commodities, trades at $19.98, up 0.6% today, with a bullish technical signal from moving averages. The fund has delivered strong performance, rising 45.66% year-to-date through Q3 2026, driven by energy and agricultural gains amid geopolitical tensions. Short interest surged 215.4% in September 2026, indicating increased bearish speculation, while institutional investments from firms like Arlington Capital and Advisortrust Partners show confidence.
The outlook remains positive due to robust commodity trends, but risks include heightened short interest and geopolitical volatility. Investors benefit from broad commodity exposure without K-1 tax complexity, though price swings from supply shocks or economic shifts pose challenges. The fund's momentum and defensive appeal in uncertain markets support a favorable view, but monitoring short-term pressure is essential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
